The Federal Antimonopoly Service (FAS) of the Russian Federation has approved prices for the first antitumor generic with INN eribulin. This was reported by the FAS press service.
“The agreed marginal prices for Eribulin-Promomed produced by AO Biokhimik are 27% lower than the prices for the foreign-made reference drug. This will make it more affordable for Russian citizens,” the report says.
The approved price of one vial of the domestic drug is 17,476 rubles, while the marginal cost of a similar vial of the reference drug is 23,794 rubles, the Federal Antimonopoly Service stressed.
The FAS previously approved the price of Convacel COVID vaccine.
